Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Organogenesis ORG -- Ignore unavailable to you. Want to Upgrade?

To: Andrew Abrams who wrote (1137)	11/4/1998 11:00:00 AM
From: Link Lady	Read Replies (1) \| Respond to of 1223

newsalert.com Organogenesis Announces October Growth in Number of Sites Using Apligraf Business Wire - November 04, 1998 09:14 CANTON, Mass.--(BUSINESS WIRE)--Nov. 4, 1998--Organogenesis Inc. (AMEX:ORG) today announced further expansion in the number of medical centers that have ordered and that have re-ordered Apligraf(R), leading indicators of product market acceptance. Between September and October 1998, the number of US centers that have ordered Apligraf grew from 135 to 192. During the same time period, the number of centers that re-ordered Apligraf increased from 56 to 94. Both increases are the largest of any month to date. Apligraf was launched in June in the US, and is marketed by Novartis Pharmaceutical Corporation. Month # Sites Buying Apligraf(1) June 8 July 38 August 80 September 135 October 192 (1)Have ordered Apligraf one or more times since launch Month # Sites Re-Ordering Apligraf(2) June 2 July 9 August 24 September 56 October 94 (2)Have re-ordered Apligraf one or more times since launch Novartis sponsored two major Apligraf events at the American College of Surgeons national meeting in Orlando the last week of October. Over one hundred physicians attended the Novartis-sponsored symposium, "Wound Care: The Future is Here", the morning of Sunday, October 25. A large number of physicians also visited the Novartis exhibit dedicated to Apligraf at the meeting to learn more about the product. During the next three weeks, Novartis will be sponsoring major Apligraf events at two more national medical meetings - an exhibit at the Art & Science of Wound Management meeting in San Diego and an exhibit plus an educational symposium at the 25th Annual Symposium on Current Critical Problems. These events are part of the comprehensive Apligraf medical education program being sponsored by Novartis. Apligraf is the only product made of living human cells to demonstrate efficacy in a large controlled trial and gain FDA approval. Apligraf looks and feels like human skin. Like human skin, Apligraf is bilayered, with both a lower dermal and an upper epidermal layer. The lower layer consists of living human dermal cells (fibroblasts) in an organized connective tissue matrix. The upper layer contains living human epidermal cells (keratinocytes) organized to form the differentiated strata of the human epidermis. Organogenesis Inc. designs, develops and manufactures medical products containing living cells and/or natural connective tissue. The Company's product development focus includes living tissue replacements, cell-based organ assist devices and other tissue-engineered products. Lead product Apligraf has been approved for the treatment of venous leg ulcers in the US and Canada; Novartis Pharma AG has global Apligraf marketing rights. Organogenesis' portfolio also includes the GRAFTPATCH(tm) surgical product (also FDA-cleared for marketing), VITRIX(tm) connective tissue replacement product, injectable engineered collagen, a bioartificial liver and a vascular graft.